摘要
本文以奥美沙坦的药物专利为研究实例,首先介绍了原研药企在奥美沙坦正式上市前的世界专利申请布局,然后描述了奥美沙坦仿制药企的典型申请及在中国的专利申请状况,而后从侵权诉讼和专利到期两个角度观察原研药企与仿制药企之间的冲突与竞争,总结相关经验,以期为我国制药行业提供相关参考。
In this paper, we took olmesartan drug patents for instance, first introduced the distribution of patent applications about olmesartan from the originator premarketing, then described typical application and the patent application status of olmesartan from the generic drugmakers in China. Then we analyzed the conflict and competition between originator and generic drugmakers from infringement litigation and patent expiration, and summarized relevant experience in order to provide references for pharmaceutical companies in China.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2015年第16期1806-1809,1819,共5页
Chinese Journal of New Drugs
关键词
奥美沙坦
仿制药物
创新药物
专利申请
olmesartan
branded drug
generic drug
patent applications
